Pfizer reports its COVID-19 vaccine trial data shows long-term efficacy in adolescents

Primary tabs

Pfizer reports its COVID-19 vaccine trial data shows long-term efficacy in adolescents

Nov 22 (Reuters) - Pfizer Inc (PFE.N) said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech (22UAy.DE) will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above ...

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 
Groups this Group Post belongs to: 
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks
Page loaded in 0.456 seconds.